Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat for Anemia in Hemodialysis (FO2RWARD-2)
NCT03799627Phase 2Completed
- Sponsor
- Akebia Therapeutics
- Start
- Jan 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vadadustat in anemia (2 arms), sponsored by Akebia Therapeutics. Primary endpoints: Mean Change in Hemoglobin Between Baseline and the Primary Evaluation Period (PEP), Number of Participants With Treatment-emergent Adverse Events and 3 more. Started Jan 2019; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03799627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799627.